Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $95.04 USD
Change Today +0.79 / 0.84%
Volume 326.1K
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$93.51
Previous Close
$94.25
Day High
$95.64
Day Low
$93.10
52 Week High
08/5/15 - $112.40
52 Week Low
10/9/14 - $41.99
Market Cap
1.9B
Average Volume 10 Days
422.5K
EPS TTM
$1.12
Shares Outstanding
19.9M
EX-Date
04/3/07
P/E TM
84.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Incorporated Appoints Matthew Korenberg as Vice President, Finance and Chief Financial Officer

Ligand Pharmaceuticals Incorporated announced the appointment of Matthew Korenberg as Vice President, Finance and Chief Financial Officer. Mr. Korenberg is expected to join Ligand’s management team on August 6, 2015. Mr. Korenberg joins Ligand from NeuroCircuit Therapeutics, where he was founder and Chief Executive Officer.

Ligand Pharmaceuticals Incorporated Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter, Second Half and Revises Earnings Guidance for the Full Year 2015

Ligand Pharmaceuticals Incorporated announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $18,418,000 compared to $10,608,000 for the same period a year ago. Gains from operations were $4,365,000 against $1,358,000 a year ago. Net income was $23,564,000 or $1.11 per diluted share against $1,592,000 or $0.07 per diluted share a year ago. Adjusted net income was $38,481,000 or $1.81 per diluted share against $5,168,000 or $0.24 per diluted share a year ago. The company generated operating cash of $17.6 million, a significant increase over $6.6 million of operating cash generated in the second quarter of 2014. The significant increase on operating cash flow illustrates the leverage in Ligand's business model of growing royalties and top line revenues combined with a low-cost infrastructure. The primary driver of the increase in adjusted earnings was due to the impact of the Viking Therapeutics IPO. For the six months, the company reported net sales of $33,020,000 compared to $26,566,000 for the same period a year ago. Gains from operations were $7,715,000 against $6,458,000 a year ago. Net income was $24,318,000 or $1.16 per diluted share against $3,688,000 or $0.17 per diluted share a year ago. Adjusted net income was $45,362,000 or $2.16 per diluted share against $12,511,000 or $0.57 per diluted share a year ago. The company reaffirms earnings guidance for full year 2015. For the year, the company expects total revenues to be between $81.0 million and $83.0 million, and adjusted earnings per diluted share to be between $3.45 and $3.50. The adjusted earnings per share guidance for both the full year and second half of 2015 exclude changes in contingent liabilities, mark-to-market adjustment for investments owed to licensors, noncash stock-based compensation expense, equity and net losses of Viking and noncash debt-related costs. The company will continue to pay cash taxes of less than 5%. For the second half of 2015, the company expects total revenues to be between $48.0 million and $50.0 million, and adjusted earnings per diluted share to be between $1.29 and $1.34. Approximately one-third of the second half revenue and earnings outlook is projected for the third quarter.

Ligand Pharmaceuticals Incorporated Enters into Commercial License and Supply Agreement with Sanofi for Captisol-Enabled SAR-125844

Ligand Pharmaceuticals Incorporated announced it has entered into a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor. Under the terms of the license, Ligand will be eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $95.04 USD +0.79

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.02 USD +0.38
Allergan plc $308.01 USD -3.99
Johnson & Johnson $95.17 USD -1.05
Pfizer Inc $32.66 USD -0.60
Valeant Pharmaceuticals International Inc C$312.05 CAD +1.60
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 61.2x
Price/Sales 26.4x
Price/Book 27.3x
Price/Cash Flow 57.8x
TEV/Sales 21.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.